Treatment of Inflammatory Bowel Disease with Biologics

145

(continued)

Molnar et al. [^43

]

121

Prospective observational

45% (1 year)

Previous biologic therapy

Gender, concurrent steroid use at biologic initiation, high CRP, smoking status

50%

(85% with concomitant IMM)

Dose intensification of biologic therapy

Annunziata et al. [

78

]

16

Retrospective

62.5% (5 years)

Absence of normalized intestinal wall thickness

(% on IMM not available)

Ampuero et al. [^44

]

75

Retrospective

30.9% (1 year)

CRP > 5 mg/L

Gender, smoking status, location, duration of treatment

100%

(100% concomitant IMM)

Younger age at diagnosis

Molnar et al. [^53

]

50

Retrospective

56% (1 year)

Fistula

Location of disease

Smoking status

(86% concomitant IMM)

Papamichael et al. [

66

]

100

Retrospective (84% with concomitant IMM)

48% (10 years)

Age at diagnosis <25 (multivariate analysis)

Disease location, behavior (perianal), fistulizing disease, type of infliximab therapy (episodic or scheduled), number of infliximab infusions, CRP, previous ileocolonic resection, smoking at initiation of infliximab, IMM or type of IMM after infliximab cessation, positive ATIs during infliximab therapy or at the time of infliximab cessation

10 Cessation of Biologics: Can It Be Done?